Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now

Cooper Companies' premium lens migration, MiSight growth and fertility recovery offer long-term upside despite Asia-Pacific, tariff and FX pressures.

Zacks Investment Research • Aug 13, 2026

The Cooper Companies (COO) Upgraded to Buy: Here's What You Should Know

The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Aug 5, 2026

CooperCompanies Announces Release Date for Third Quarter 2026

SAN RAMON, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report third quarter 2026 financial results on Wednesday, September 9, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

GlobeNewsWire • Jul 30, 2026

Oakmark Global All Cap Strategy Q2 2026 Portfolio Performance

The portfolio's return was 8.05% (net) for the reporting period. Shares of Samsung Electronics rallied on the back of record first-quarter operating profit, driven by strong AI-related demand across its semiconductor business. As the quarter progressed, elevated medical cost trends began to stabilize, easing pressure on managed care earnings.

Seeking Alpha • Jul 29, 2026

The London Company QTD Mid Cap Q2 2026 Contributors, Detractors And Trades

The London Company Mid Cap portfolio returned 9.7% (9.5% net) during the quarter vs. a 13.8% increase in the Russell Midcap Index. The market was led by momentum and high-beta factors — in fact, the top beta quintile returned over 44% and drove nearly two-thirds of the index's gain. ENTG was a top contributor, benefiting from improving semiconductor demand, accelerating AI investment, and rising fab utilization.

Seeking Alpha • Jul 28, 2026

Oakmark Global Fund Q2 2026 Portfolio Activity

Recent concerns over United States regulations have overshadowed AstraZeneca's merits and weighed on the broader pharmaceutical industry. We were pleased to initiate a position in Cooper Companies at what we view as an attractive entry point relative to our estimate of intrinsic value. We expect the industry to recover to historical levels and believe LVMH can further benefit from self-help initiatives in the form of product innovation and improved cost discipline.

Seeking Alpha • Jul 24, 2026

Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jul 21, 2026

Reasons to Retain Cooper Companies Stock in Your Portfolio for Now

Cooper Companies' premium contact lenses, restructuring gains and product launches support growth despite regional and competitive headwinds.

Zacks Investment Research • Jul 16, 2026

Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jul 15, 2026

CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure

SAN RAMON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, released today its 2025 Corporate Sustainability Report. The report showcases the company's commitment to people and planet, supported by expanded performance metrics and continued progress on sustainability priorities. A key milestone in this year's report is the company's first-time disclosure of Scope 3 greenhouse gas emissions, enhancing transparency and strengthening its sustainability reporting.

GlobeNewsWire • Jun 30, 2026